Payment overview · 2025
General Payments
$140.58
7 reported records · 5 companies
Healthcare provider profile · identity verified
William H Long, MD
Allopathic & Osteopathic Physicians|Family Medicine · HARTSVILLE, SC · NPI 1104858489
Verified facts
What the public records show
CMS Open Payments records show William H Long, MD received $140.58 in general payments during 2025 across 7 reported records.
Exact Sciences Corporation accounted for 30.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $43.35 | 30.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.14 | 23.6% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $28.68 | 20.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.01 | 12.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.40 | 12.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $140.58 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $43.35 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.14 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.14 | 2 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $28.68 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.01 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 55 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1215 | 130 |
| Meloxicam | Meloxicam | 481 | 99 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 446 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 338 | 83 |
| Atorvastatin Calcium | Atorvastatin Calcium | 313 | 91 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 285 | 81 |
| Omeprazole | Omeprazole | 246 | 64 |
| Amitriptyline Hcl | Amitriptyline Hcl | 212 | 38 |
| Montelukast Sodium | Montelukast Sodium | 194 | 47 |
| Prednisone | Prednisone | 193 | 110 |
| Lisinopril | Lisinopril | 187 | 49 |
| Metformin Hcl | Metformin Hcl | 176 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 167 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 166 | 45 |
| Losartan Potassium | Losartan Potassium | 132 | 38 |
| Oxycodone Hcl | Oxycodone Hcl | 131 | 14 |
| Levothyroxine Sodium | Levothyroxine Sodium | 124 | 37 |
| Azithromycin | Azithromycin | 110 | 80 |
| Naproxen | Naproxen | 110 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 109 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 108 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 103 | 23 |
| Famotidine | Famotidine | 101 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 98 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 28 |
| Glipizide | Glipizide | 82 | 23 |
| Gabapentin | Gabapentin | 80 | 28 |
| Potassium Chloride | Potassium Chloride | 77 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 72 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 72 | 20 |
| Chlorthalidone | Chlorthalidone | 70 | 22 |
| Doxepin Hcl | Doxepin Hcl | 68 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 17 |
| Carvedilol | Carvedilol | 67 | 18 |
| Alprazolam | Alprazolam | 64 | suppressed |
| Trulicity | Dulaglutide | 64 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 63 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 63 | 18 |
| Trazodone Hcl | Trazodone Hcl | 63 | 11 |
| Naloxone Hcl | Naloxone Hcl | 60 | 55 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | suppressed |
| Colchicine | Colchicine | 59 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 56 | 38 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | suppressed |
| Furosemide | Furosemide | 56 | 23 |
| Clonidine Hcl | Clonidine Hcl | 55 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 14 |
| Jardiance | Empagliflozin | 55 | 14 |
| Celecoxib | Celecoxib | 52 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 52 | 14 |
| Simvastatin | Simvastatin | 49 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 24 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 48 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 48 | 17 |
| Allopurinol | Allopurinol | 47 | 11 |
| Clonazepam | Clonazepam | 47 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 45 | 17 |
| Ozempic | Semaglutide | 44 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 44 | 15 |
| Atenolol | Atenolol | 40 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 27 |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 33 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 33 | suppressed |
| Ezetimibe | Ezetimibe | 32 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 15 |
| Mupirocin | Mupirocin | 29 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Tradjenta | Linagliptin | 28 | suppressed |
| Eliquis | Apixaban | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 24 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 18 | suppressed |
| Roflumilast | Roflumilast | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 14 |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 11 |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $140.58 · 7 records | Exact Sciences Corporation | AIRSUPRA, Cologuard Collection Kit, JARDIANCE, NUPLAZID, OTEZLA, REPATHA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error